RxDoctor Payments Data

Bipin Patel, MD

Neurology · Valdosta, GANPI 1356453914

Payments from drug & device makers

$13,402in general payments, 2019–2025

Across 690 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • SK Life Science, Inc.$1K
  • UCB, Inc.$753
  • Lundbeck LLC$629
  • Amgen$587
  • Novartis$478
  • plus $8K from 52 others

What the payments were for

  • Speaking & faculty fees$1641%
  • Food & beverage$13,07798%
  • Education$1601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)124$1,570
SK Life Science, Inc.42$1,037
UCB, Inc.41$753
Lundbeck LLC22$629
Amgen(2 entities)22$587
Novartis19$478
Teva Pharmaceuticals USA, Inc.18$452
Eisai Inc.21$429
Neurelis, Inc.23$393
Sunovion Pharmaceuticals Inc.27$385
Lilly USA, LLC19$378
Pfizer26$375
Jazz Pharmaceuticals Inc.17$374
Greenwich Biosciences, Inc.15$373
Kyowa Kirin, Inc.18$353
Sumitomo Pharma America, Inc.16$297
Supernus Pharmaceuticals, Inc.14$288
Harmony Biosciences LLC14$271
Impel Pharmaceuticals Inc.14$238
EMD Serono, Inc.13$232
Merz North America, Inc.7$224
AstraZeneca8$205
Sanofi12$198
Tanabe Pharma America, Inc.14$194
Neurocrine Biosciences, Inc.7$165
Acorda Therapeutics, Inc10$164
Biogen8$164
Avanir Pharmaceuticals, Inc.10$160
Adamas Pharmaceuticals, Inc.10$159
E.r. Squibb & Sons, L.L.C.3$144
Otsuka America Pharmaceutical, Inc.3$137
Medtronic3$137
Inspire Medical Systems, Inc.1$119
CSL Behring5$118
Genentech USA, Inc.5$111
Ipsen Biopharmaceuticals, Inc6$106
Merz Pharmaceuticals, LLC5$102
Catalyst Pharmaceuticals, Inc.5$102
Biohaven Pharmaceuticals, Inc.4$96
Livanova USA, Inc.2$85
Amneal Pharmaceuticals LLC6$83
Almatica Pharma LLC4$61
ANI Pharmaceuticals, Inc.3$54
Alnylam Pharmaceuticals Inc.3$52
Biohaven Pharmaceutical Holding Company Ltd.3$46
Grifols USA, LLC2$41
Johnson & Johnson3$40
Acadia Pharmaceuticals Inc2$37
Argenx US, Inc.1$35
Philips North America LLC1$32
MDD US Operations, LLC1$26
Strongbridge US Inc.2$22
Zogenix Inc.1$20
TG Therapeutics, Inc.1$18
Mirum Pharmaceuticals, Inc.1$16
GRT US Holding, Inc.1$13
Assertio Therapeutics, Inc.1$12
Mallinckrodt Hospital Products Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,402 in reported general payments places this provider in the 75th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$52,207
Medicare patients
243
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate14$58,070
XcopriCenobamate23$45,261
FycompaPerampanel22$41,878
Aimovig AutoinjectorErenumab-Aooe35$31,554
UbrelvyUbrogepant23$30,968
BriviactBrivaracetam22$28,836
QuliptaAtogepant12$14,032
Carbamazepine ErCarbamazepine33$6,218
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen237$4,624
Gabapentin196$3,833
Oxcarbazepine43$3,761
Topiramate133$3,737
Levetiracetam133$3,221
Lacosamide27$2,784
Tizanidine Hcl163$2,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$385$58,07014 claims
SK Life Science, Inc.Xcopri$1,037$45,26123 claims
AbbVieUbrelvy, Qulipta$1,570$45,00035 claims
Eisai Inc.Fycompa$429$41,87822 claims
UCB, Inc.Briviact$753$28,83622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 506 neurology providers in Georgia.

Other neurology in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →